Dr Paul Kelly

|   Healthcare  

|   Location: Sydney, AU

Paul is a Co-Founder & Venture Partner at OneVentures, focusing on the Healthcare and Biotechnology practice. He serves on the Investment Committees for Fund I, Fund II and Fund III.

With over 30 years of experience in biomedical innovation, Paul provides strategic guidance to portfolio companies. He is a Non-Executive Director for BiVACOR. Previously, he served on the boards of Vaxxas (Chair), Hatchtech (Chair, licensed to NYSE:DRL), CharmHealth (acquired by ASX:CGL), Clinical Genomics (Enterix acquired by 3TM), Blade, Prota Therapeutics and Find Me.

As Co-Founder of Gemini Genomics (NASDAQ:GMNI), he led their IPO (US$250M valuation) before its merger with Sequenom (NASDAQ:SQNM). Earlier in his career, he co-founded Agamatrix, a bio-sensing medical device company operating in the US and Southeast Asia as well as Atomera (NASDAQ:ATMR). As CEO of Orchid Cellmark (NASDAQ:ORCH), he drove a tenfold valuation increase and significant revenue growth.

Paul began his career as a researcher and endocrinologist at St Vincent’s Hospital Sydney before transitioning into biotechnology. In the US, he held executive roles in leading biotech and medical companies driving the growth of several industry leaders.

He has authored over 100 publications in leading journals and is a Non-Executive Director at the Garvan Institute of Medical Research, a member of the UNSW Medicine Dean’s Advisory Group and serves on the Advisory Board of the Australian Government’s Australia’s Economic Accelerator (AEA) program.

Paul holds medical degrees from UNSW and is a Fellow of the Royal Australasian College of Physicians.

|   MBBS (Hons), MD, FRACP